Comparative Pharmacology
Head-to-head clinical analysis: COR OTICIN versus CYCLOCORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COR OTICIN versus CYCLOCORT.
COR-OTICIN vs CYCLOCORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
COR-OTICIN is a combination product containing hydrocortisone (a corticosteroid with anti-inflammatory and immunosuppressive properties) and neomycin (an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit) and polymyxin B (a polymyxin antibiotic that disrupts bacterial cell membrane permeability).
Topical corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive actions. Suppresses cytokine production, inhibits phospholipase A2, and reduces prostaglandin synthesis.
1-2 drops in each affected ear twice daily for 7 days.
Apply a thin film topically to affected area twice daily (morning and evening). Not for ophthalmic use.
None Documented
None Documented
Terminal half-life 4-6 hours; prolonged in renal impairment (up to 12-15 hours)
3.5 hours (terminal); clinical effect duration longer due to tissue binding.
Renal (60-80% unchanged), fecal/biliary (5-10%)
Primarily hepatic metabolism; inactive metabolites excreted renally (<1% unchanged) and in feces (biliary).
Category C
Category C
Topical Corticosteroid + Antibiotic
Topical Corticosteroid